Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia.

Saxon D Smith, Simon Fifer, Meredith Edwards, Anne Walter, Yichen Zhong, Joe Zhuo, Bronwyn West, Lynda Spelman
{"title":"Tradeoffs and decision-making in moderate to severe psoriasis for oral versus injectable treatments: data from patients and dermatologists in Australia.","authors":"Saxon D Smith, Simon Fifer, Meredith Edwards, Anne Walter, Yichen Zhong, Joe Zhuo, Bronwyn West, Lynda Spelman","doi":"10.1080/09546634.2024.2339440","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Oral systemic and injectable biologic treatments are available in Australia to treat moderate to severe psoriasis.</p><p><strong>Objective: </strong>To examine how patients and dermatologists in Australia choose between oral and injectable treatments for psoriasis.</p><p><strong>Methods: </strong>In this discrete choice experiment (DCE), adults with moderate to severe psoriasis and dermatologists were asked to choose between 2 treatments labeled by mode of administration ('oral' or 'subcutaneous injection'), each with randomly assigned levels for 9 treatment attributes. Needle fear was rated by patients.</p><p><strong>Results: </strong>Completed surveys from 178 patients and 43 dermatologists were included in the analysis. Symptom reduction, safety, and mode of administration were attributes found to have a significant impact on treatment choice; dosing frequency was a significant attribute for the injectable option. When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease. Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear.</p><p><strong>Limitations: </strong>Participation bias may limit the generalizability of these findings.</p><p><strong>Conclusion: </strong>Participants preferred oral over injectable treatment for moderate psoriasis. These findings corroborate the need for efficacious oral therapies to treat the disease.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2339440"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2024.2339440","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Oral systemic and injectable biologic treatments are available in Australia to treat moderate to severe psoriasis.

Objective: To examine how patients and dermatologists in Australia choose between oral and injectable treatments for psoriasis.

Methods: In this discrete choice experiment (DCE), adults with moderate to severe psoriasis and dermatologists were asked to choose between 2 treatments labeled by mode of administration ('oral' or 'subcutaneous injection'), each with randomly assigned levels for 9 treatment attributes. Needle fear was rated by patients.

Results: Completed surveys from 178 patients and 43 dermatologists were included in the analysis. Symptom reduction, safety, and mode of administration were attributes found to have a significant impact on treatment choice; dosing frequency was a significant attribute for the injectable option. When treatment attributes were held equal, patients and dermatologists preferred oral versus injectable treatments for moderate disease. Patients with higher levels of needle fear were more likely to favor an oral treatment versus patients with lower levels of needle fear.

Limitations: Participation bias may limit the generalizability of these findings.

Conclusion: Participants preferred oral over injectable treatment for moderate psoriasis. These findings corroborate the need for efficacious oral therapies to treat the disease.

中度至重度银屑病口服治疗与注射治疗的权衡与决策:来自澳大利亚患者和皮肤科医生的数据。
背景:澳大利亚有治疗中度和重度银屑病的口服和注射生物制剂:在澳大利亚,口服系统性治疗和注射生物治疗可用于治疗中度至重度银屑病:研究澳大利亚患者和皮肤科医生如何在银屑病口服治疗和注射治疗之间做出选择:在这项离散选择实验(DCE)中,患有中度至重度银屑病的成人和皮肤科医生被要求在两种治疗方法("口服 "或 "皮下注射")之间做出选择,每种治疗方法都有随机分配的 9 个治疗属性水平。患者对打针恐惧感进行了评分:结果:178 名患者和 43 名皮肤科医生填写的调查问卷被纳入分析。结果发现,减轻症状、安全性和给药方式对治疗选择有显著影响;给药频率是注射选择的一个重要属性。在治疗属性相同的情况下,对于中度疾病,患者和皮肤科医生更倾向于口服治疗,而不是注射治疗。对针头恐惧程度较高的患者与对针头恐惧程度较低的患者相比,更倾向于口服治疗:局限性:参与偏差可能会限制这些发现的普遍性:结论:对于中度银屑病,参与者更倾向于口服治疗,而非注射治疗。这些研究结果证实,治疗银屑病需要有效的口服疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信